GlassScriptPhysician profile
Mobin P Ghavami
NPI 1447239744
$14,316.42
in general payments reported to CMS, 2019-2025
40 companies · $3,819 in 2025
The $3,819 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $2,422 · 2021: $3,251 · 2022: $412 · 2023: $1,340 · 2024: $1,585 · 2025: $3,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,743.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $4,417.20 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Astrazeneca Pharmaceuticals LP | $2,050.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $865.66 | 2019-2025 | Jardiance |
| Abbvie INC. | $839.93 | 2020-2025 | |
| Lilly USA, LLC | $741.29 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $732.58 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $658.18 | 2024-2025 | Korlym |
| Intra-Sana Laboratories | $558.88 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Pfizer INC. | $548.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $305.88 | 2019 | |
| Amgen INC. | $304.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Ani Pharmaceuticals, INC. | $224.93 | 2025 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $219.18 | 2022-2025 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $210.22 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $187.78 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mobin Ghavami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.